| abstract |
(57) The present invention relates to a disease state in response to inhibition of abl-, PDGF-receptor- and / or Kit receptor-tyrosine kinases, abl-, PDGF-receptor- and / or It relates to the combination of a Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to α 1 -acid glycoprotein (AGP) and to formulations and / or treatments. In particular, the invention relates to fixed combinations or time-lags with organic compounds capable of binding abl-, PDGF-receptor- and / or Kit receptor-tyrosine kinase inhibitors to α 1 -acid glycoprotein (AGP). Or a product or combination comprising either for simultaneous administration and treated by inhibition of proliferative diseases, in particular tumor diseases, in particular abl-, PDGF-receptor- and / or Kit receptor-tyrosine kinase activity. It relates to the combined use of both classes of compounds, either in fixed combinations or for time-lag or simultaneous administration, to treat the resulting disease. |